Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global X Copper Miners ETF (COPX) vs Zoetis Inc (ZTS) Price & Performance

Global X Copper Miners ETFTrade
Zoetis IncTrade

Price performance (Past 24H)

Key statistics

Global X Copper Miners ETF vs Zoetis Inc — how do they compare? Global X Copper Miners ETF trades at $88.63, while Zoetis Inc trades at $72.94 (market cap $31.14B). The key difference: Zoetis Inc pays a 2.81% dividend while Global X Copper Miners ETF pays none, and Global X Copper Miners ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.

COPXZTS
Sector
Commodities - Metals/AgricultureHealth
52-Week High
$95.70$156.76
52-Week Low
$46.08$71.91
Market Cap
$31.14B
Enterprise Value
$38.70B
Dividend Yield
2.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global X Copper Miners ETF

COPX, the Global X Copper Miners ETF, trades at $89.43, down slightly by 0.09% today. The technical outlook is bullish based on moving averages, but oscillators signal caution with RSI levels indicating overbought conditions. Recent news highlights institutional accumulation, with 180 Wealth Advisors increasing its stake by 28.1% in Q2 2026 (SEC filing, August 6, 2026). The ETF is positioned to benefit from copper demand driven by AI infrastructure and electrification trends.

The investment case for COPX hinges on structural copper demand growth from AI data centers and green energy, though it faces risks from commodity price volatility and mining supply constraints. Analysts view the recent pullback as a buying opportunity, citing operational leverage to copper prices. Key risks include cyclical mining downturns and execution challenges among constituent companies.

Zoetis Inc

Zoetis (ZTS) trades at $72.42, down 3.27% amid bearish technical signals and recent earnings pressure. The stock shows strong fundamentals with 27.69% net margins and 64.91% ROE, but faces headwinds from softening pet healthcare demand. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a lowered 2026 outlook. Analyst consensus remains positive with a $94.90 price target despite near-term challenges.

The outlook remains cautiously optimistic given ZTS's dominant market position and profitability, though near-term performance depends on reversing companion animal segment weakness. Investment opportunity exists at current discounted valuation (P/E 12.29), balanced against competitive pressures and class action litigation risks. Upside potential aligns with analyst targets if execution improves.

Returns comparison

Trailing returns across standard periods

About Global X Copper Miners ETF

COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.

Read more on COPX

About Zoetis Inc

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Read more on ZTS